Relapsed/Refractory Multiple Myeloma Treatment Decision Making
Three experts on multiple myeloma review a patient case and discuss best practices and treatment strategies for patients with relapsed/refractory multiple myeloma.
EP. 3: Role of GPRC5D in R/R MM Patients
January 18th 2024An expert briefly reviews the role of GPRC5C-targeting bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM) following four previous lines of therapy, comparing its efficacy and characteristics with other treatment options like BCMA and CAR-T therapies. She also provides insights into the benefits, risks, and potential challenges related to the access and utilization of GPRC5D-targeting bispecifics, providing a comprehensive overview of considerations in the advanced R/R MM treatment landscape.
EP. 6: Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D Bispecific
January 25th 2024Oncology Clinical Pharmacist Specialist Amir Ali delves into potential challenges related to access and the use of this therapy, providing a comprehensive perspective on the complexities of incorporating GPRC5-targeting bispecifics into R/R MM patient management.
EP. 8: Patient-Centric Care in R/R MM
February 1st 2024Nurse Linne-Mclaren provides her insights into the proactive measures, monitoring strategies, and experiences related to talquetamab-associated adverse events, along with a broader perspective on prophylactic measures for managing potential adverse events in bispecific therapies.
EP. 9: Guiding Through Challenges: Insights for Caregivers of R/R MM Patients
February 1st 2024Ursula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.
